DOR BioPharma, Inc. (now Soligenix, Inc.)

Corporate Snapshot

DOR BioPharma, Inc. ("DOR" or "the Company") is a biopharmaceutical company addressing life-threatening side effects of cancer and cancer treatments, serious gastrointestinal diseases and disorders, and biodefense countermeasures. The Company's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid being developed to treat gastrointestinal Graft-versus-Host Disease (GI GVHD). GI GVHD is a rare disorder that can strike people whose immune system is suppressed after receiving allogeneic hematopoietic stem cell transplantation (HSCT) for cancer or that have gastrointestinal disorders characterized by severe inflammation. Symptoms of GI GVHD may include skin rash, intestinal problems similar to colitis, and liver dysfunction. DOR has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the treatment of GI GVHD, and has received a PDUFA date of July 21, 2007. In addition, the FDA's Oncology Drug Advisory Committee (ODAC) is to review the NDA for orBec® on May 9, 2007. An MAA with the EMEA for orBec® has also been filed and validated. orBec® may additionally have application in treating other gastrointestinal disorders characterized by severe inflammation. The Company is concurrently developing biodefense countermeasures pursuant to the paradigm established by the Project BioShield Act of 2004, which provides incentives for industry to expeditiously supply biodefense countermeasures to the Strategic National Stockpile (SNS). DOR's biodefense products in development are bioengineered vaccines to protect against the deadly effects of ricin toxin (with a vaccine called RiVax™) and botulinum toxin (with a vaccine called BT-VACC™)—both considered serious bioterrorism threats. The Company has headquarters in Miami, Florida.